A single arm confirmatory study of pembrolizumab in patients with previously untreated advanced sarcomatoid carcinoma of the lung

Phase 2

• Conditions: Advanced sarcomatoid carcinoma of the lung

• Registration Number: JPRN-UMIN000027629
• Lead Sponsor: Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-06-12
• Study Completion: 2022-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up continuing
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

Not provided

Exclusion Criteria

1. Active auto-immune disease 2. Interstitial lung disease or pulmonary fibrosis 3. Active infection such as bacteria, HBV, or HCV

Study & Design

• Study Type: Interventional
• Study Design: Not specified